Screening for neurofilament inclusion disease using alpha-internexin immunohistochemistry

Neurology. 2005 May 10;64(9):1658-9. doi: 10.1212/01.WNL.0000160328.17975.9C.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Amyotrophic Lateral Sclerosis / diagnosis
  • Amyotrophic Lateral Sclerosis / metabolism
  • Brain / metabolism
  • Brain / pathology*
  • Brain / physiopathology
  • Carrier Proteins / analysis
  • Carrier Proteins / metabolism*
  • Dementia / diagnosis
  • Dementia / metabolism
  • Diagnosis, Differential
  • Female
  • Humans
  • Immunohistochemistry
  • Inclusion Bodies / metabolism
  • Inclusion Bodies / pathology*
  • Intermediate Filament Proteins
  • Intermediate Filaments / metabolism
  • Intermediate Filaments / pathology*
  • Male
  • Middle Aged
  • Multiple System Atrophy / diagnosis
  • Multiple System Atrophy / metabolism
  • Neurodegenerative Diseases / diagnosis*
  • Neurodegenerative Diseases / metabolism
  • Neurodegenerative Diseases / physiopathology
  • Neurons / metabolism
  • Neurons / pathology*
  • Parkinsonian Disorders / diagnosis
  • Parkinsonian Disorders / metabolism
  • Predictive Value of Tests
  • Pyramidal Tracts / metabolism
  • Pyramidal Tracts / pathology
  • Tauopathies / diagnosis
  • Tauopathies / metabolism

Substances

  • Carrier Proteins
  • Intermediate Filament Proteins
  • alpha-internexin